Pharmaxis Completes Phase II clinical study with ASM8 in asthma patients

11th Mar 10

Release Date: 11/03/2010 12:00am

Pharmaxis Ltd today announced the successful completion of a Phase IIa dose profiling study with its new anti-inflammatory agent ASM8 in patients with allergic asthma.


Read full media release - pdf

Categories: News and Media